Medtide, Inc. Class H 3880
HKEX · Hong Kong SAR China · Health Technology
HKD 21.18-0.34 (-1.58%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ROCKLIN, Calif. & HANGZHOU, China, August 05, 2026--CPC Scientific Inc., a premier peptide and oligonucleotide-focused Contract Research, Development, and Manufacturing Organization (CRDMO) and a wholly owned subsidiary of Medtide Inc. (HKEX: 3880.HK), today announced that Chinese Peptide Company, its current Good Manufacturing Practice (cGMP) manufacturing facility, located in Hangzhou, China, has successfully completed a Pre-License Inspection (PLI) conducted by the U.S. Food and Drug Administ
Shanghai, China--(Newsfile Corp. - May 15, 2026) - On March 18, 2026, Frost & Sullivan and Forbes China Group jointly hosted the 2026 Forbes China Pioneer Innovators in Industry Development Selection Gala Banquet at the Bulgari Hotel in Shanghai. The awards, co-initiated by Forbes China Group and Frost & Sullivan, feature one main category—the "2026 Forbes China Industry Development Pioneer Innovators"—and three sub-categories: "2026 Forbes China Industry Development Leading Enterprises," "2026.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.